 |
 |
 |
 |
 |
|
            |
FOCIS Interventional Immunology Course
Course Agenda
| 7:00 – 7:45 am | Continental Breakfast |
| 7:45 – 8:00 am | Welcome & Introduction – E. William St. Clair, MD, Duke University Medical Center |
| 8:00 – 8:55 am | TNF Blockade Revisited: Shifting the Treatment Paradigm in RA E. William St. Clair, MD, PhD, Duke University Medical Center |
| 8:55 – 9:50 am | Emerging Cytokine Targets in Rheumatoid Arthritis John O’Shea, MD, National Institute of Arthritis and Musculoskeletal and Skin Diseases |
| 9:50 – 10:05 am | Break |
| 10:05 – 11:00 am | Harnessing the Th1 and Th17 Pathways for Treatment of IBD Scott Plevy, MD, University of North Carolina at Chapel Hill |
| 11:00 – 11:55 am | B Cell Directed Therapies: A Promise Realized? John Looney, MD, University of Rochester |
| 12:00 – 1:00 pm | Lunch |
| 1:00 – 1:55 pm | Redirecting Lymphocytes in Multiple Sclerosis: Natalizumab and Fingolimod Jeffrey Cohen, MD, Cleveland Clinic Foundation |
| 1:55 – 2:50 pm | Anti-CD3 Monoclonal Antibodies: Inducing Immunoregulation in Autoimmunity Kevan Herold, MD, Yale University |
| 2:50 – 3:45 pm | Translation of T Cell Costimulatory Blockade to the Clinic: CTLA4Ig and Beyond Larry Moreland, MD, University of Pittsburgh |
| 3:45 – 4:00 pm | Break |
| 4:00 – 4:55 pm | Targeting Intracellular Signaling Pathways: Trials and Tribulations Anthony Manning, PhD, Biogen Idec |
| 4:55 – 5:50 pm | T Regulatory Cells: Bench to Bedside Jeffrey Bluestone, PhD, University of California, San Francisco |
Continuing Medical Education Credit
This activity was planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the A. Webb Roberts Center for Continuing Education of Baylor Health Care System, Dallas, and the Federation of Clinical Immunology Societies. The A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System, Dallas, is accredited by the ACCME to provide continuing medical education for physicians.The A. Webb Roberts Center for Continuing Education of Baylor Health Care System, Dallas, designates this educational activity for 8.25 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Learning Objectives
At the conclusion of the activity, the participant should be able to:- Identify the scientific basis for choice of immunogically related therapeutic targets in various diseases, including organ specific and systemic autoimmunity, allergy, transplant rejection, cancer, and HIV.
- Explain the rationale and mechanism underlying the major pharmacologic approaches for interventional immunology in current practice including, anti-cytokine therapy, costimulatory blockade, lymphocyte depletion, adhesion-molecule blockade, and signaling/lymphocyte activation blockade.
- Evaluate the track record of the different therapeutic approaches in different specialties.
- Recognize the cross-disciplinary lessons that can be learned from the clinical experience with specific interventions including pharmacological issues, limitations in altering disease progression and complications due to immunosuppression (infections, neoplasias).
- Analyze how a physician should decide to use and choose therapies.
© 2008 FOCIS